"Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection"
2020-07-04
عنوان الدراسة
"Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection"
داعم الدراسة
Janssen-Cilag International NV
دواء الدراسة
TMC435 (simeprevir) / Pegylated interferon alfa-2a (PegIFNα-2a) / Ribavirin (RBV)
رقم بروتوكول الدراسة
TMC435HPC3014
حالة الدراسة
Completed
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)_ King Abdulaziz Medical City NG (Riyadh)_ King Khalid University Hospital (Riyadh)
مرحلة الدراسة
3b
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。